Supplemental Table 1 – Frequency of anti-HIV-1 gp140 Env-specific antibody-secreting cells over total IgG memory B cells in chronically HIV-1 infected subjects.

Patient ID	Total IgG ASC/10^6 PBMC	gp140 ASC/10^6 PBMC	% of gp140 ASC over total ASC
8982-018	0	0	**n/a**
8982-019	2,619	4	**0.15**
8982-025	1,551	0	**0.00**
8982-026	2,910	10	**0.34**
8982-028	12,500	18	**0.14**
8982-029	7,417	87	**1.17**
8982-030	15,167	45	**0.30**
8982-036	337	3	**0.89**
8982-037	25,686	116	**0.45**
8982-038	30,742	0	**0.00**
8982-039	10,401	28	**0.27**
8982-040	5,937	12	**0.20**
8982-041	3,656	14	**0.38**
8982-043	68	2	**2.94**
8982-044	5,176	39	**0.75**
8982-126	3,900	4	**0.10**
8982-127	12,066	63	**0.52**
8982-128	175	0	**0.00**
8982-130	233	2	**0.86**
8982-131	325	2	**0.62**
8982-132	17	0	**0.00**
8982-133	25,641	417	**1.63**
8982-134	15,091	104	**0.69**
8982-135	5,809	14	**0.24**
8982-136	5,966	44	**0.74**
8982-137	7,441	3	**0.04**
Mean ASC/10^6 PBMC	**7,724**	**40**	**0.54**
Mean ASC/10^6 PBMC of gp140 responders	**8,016**	**49**	**0.64**

Supplemental Table 2 – MPER gp41 2F5-related epitope-specific plasma antibody levels, reported both as µg/ml 2F5 equivalents and as end-point titers, and memory IgG responses in chronically HIV-1 infected subjects.

Patient no.	ug/ml 2F5 Equivalents	End-point titers	ASC/10^6 PBMC
8982-018	<0.01	>1:6.25	**1**
8982-019	<0.01	>1:6.25	0
8982-025	<0.01	>1:6.25	**3**
8982-030	<0.01	>1:6.25	0
8982-036	**1.996**	**1:50**	0
8982-037	<0.01	>1:6.25	0
8982-038	<0.01	>1:6.25	0
8982-039	<0.01	>1:6.25	0
8982-040	**0.075**	**1:6.25**	0
8982-041	**0.069**	**1:6.25**	0
8982-126	<0.01	>1:6.25	0
8982-127	<0.01	>1:6.25	0
8982-128	<0.01	>1:6.25	0
8982-130	**1.138**	**1:25**	0
8982-131	<0.01	>1:6.25	0
8982-132	<0.01	>1:6.25	0
8982-133	<0.01	>1:6.25	0
8982-134	<0.01	>1:6.25	0
8982-135	**3.425**	**1:100**	**3**
8982-136	<0.01	>1:6.25	0
8982-137	<0.01	>1:6.25	0



Results were considered positive when above 3 times + 3SD the average OD_{405} of HIV negative subjects (representative sample in the lower right panel). Five of 21 subjects had detectable levels of MPER gp41 2F5 epitope-specific antibodies.